In the BioHarmony Drug Report Database
Romidepsin
Istodax, Romidepsin (romidepsin) is a protein pharmaceutical. Romidepsin was first approved as Istodax on 2009-11-05. It is used to treat t-cell lymphoma cutaneous and t-cell lymphoma peripheral in the USA. The pharmaceutical is active against histone deacetylase 1. In addition, it is known to target histone deacetylase 4, histone deacetylase 9, histone deacetylase 2, histone deacetylase 8, histone deacetylase 6, histone deacetylase 7, histone deacetylase 3, and histone deacetylase 5. Istodax’s patent is valid until 2021-08-22 (FDA).
Trade Name
|
Istodax, Romidepsin |
---|---|
Common Name
|
romidepsin |
ChEMBL ID
|
CHEMBL343448 |
Indication
|
t-cell lymphoma cutaneous, t-cell lymphoma peripheral |
Drug Class
|
Depsipeptide derivatives |
Image (chem structure or protein)